Clinical Trials Directory

Trials / Completed

CompletedNCT03268681

BIOtinidase Test In Optic-Neuropathy

Status
Completed
Phase
Study type
Observational
Enrollment
12 (actual)
Sponsor
Fondation Ophtalmologique Adolphe de Rothschild · Network
Sex
All
Age
Healthy volunteers
Not accepted

Summary

Biotinidase is an enzyme that recycles biotin, a water-soluble vitamin essential as a coenzyme for four carboxylases that are involved in gluconeogenesis, fatty acid synthesis, and in the catabolism of several branch-chain amino acids. Biotinidase deficiency (BD) is an autosomal recessively inherited disorder. Patients with profound BD (\<10% of mean normal serum biotinidase activity) presents, usually during early childhood, with neurological (seizures, hypotonia, ataxia, developmental delay, vision problems, and/or hearing loss) and non-neurological findings (metabolic acidosis, respiratory difficulties, alopecia and/or skin rash) that may progress to coma or death if untreated. Three cases of adult-onset biotinidase deficiency with reversible optic neuropathy have recently been described in France, where there is no neonatal screening of BP. Once treated with Biotin, patients' vision was fully restored. This study aims to assess the prevalence of BP among a population of patients with idiopathic optic neuropathy, and to assess the efficacy of Biotin supplementation on visual impairment in these patients.

Conditions

Timeline

Start date
2017-07-26
Primary completion
2018-05-30
Completion
2018-07-26
First posted
2017-08-31
Last updated
2018-10-18

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03268681. Inclusion in this directory is not an endorsement.